Curie.Bio is a new model for venture capital in biotech. We are focused on a singular mission – helping founders launch therapeutics companies that go on to raise an awesome next round of financing.
Location: Canada, Ontario, Boston
Investors 5
| Date | Name | Website |
| - | Shine Capi... | shine.vc |
| 10.07.2026 | 5AM Ventur... | 5amventure... |
| 08.11.2023 | ARCH Ventu... | archventur... |
| - | F-Prime Ca... | fprimecapi... |
| 10.01.2024 | BoxGroup | boxgroup.c... |
Mentions in press and media 6
| Date | Title | Description |
| 17.03.2026 | R1 Therapeutics: $77.5 Million Raised To Advance Kidney Disease Treatment | R1 Therapeutics, a clinical-stage biopharmaceutical company focused on kidney disease, has launched with an oversubscribed $77.5 million Series A financing to advance a first-in-class treatment for hyperphosphatemia in patients with chronic... |
| 17.03.2026 | Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306 | AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, an... |
| 17.03.2026 | R1 Therapeutics Raises $77.5M in Series A Funding | R1 Therapeutics, a Redwood City, CA-based clinical-stage biopharmaceutical company, raised $77.5M in Series A funding. The round was co-led by Abingworth, F-Prime, and DaVita Venture Group, with participation from Curie.Bio, SymBiosis, and ... |
| 31.12.2025 | В США кандидаты наук не могут найти работу из-за спада в развитии Бостонского биотехнологического центра | Газета Wall Street Journal сообщает, что некогда процветающий биотехнологический сектор Бостона переживает резкий спад, в результате чего молодые доктора наук испытывают трудности с поиском работы. Они сталкиваются с сокращением венчурного ... |
| 28.06.2024 | Therapeutics-focused VC Curie.Bio brings total funds raised to almost $1bn with final close of new vehicle | Biotech investor Curie.Bio has brought its total funds raised to almost $1bn thanks to a $380m final close of its latest |
| 14.02.2023 | New biotech VC takes off with $520M and a flight deck stacked with big-name investors ready to serve | Several biotech entrepreneurs have launched a new venture capital vehicle dubbed Curie.bio that will serve not only as a seed investor, but as a drug discovery co-pilot for founders. The company model aims to ultimately give biotechs wings ... |